ATE179611T1 - Verfahrenm zum in vitro herstellung der proteolytischen wirkung von ns3 hepatitis c virus (hcv) - Google Patents

Verfahrenm zum in vitro herstellung der proteolytischen wirkung von ns3 hepatitis c virus (hcv)

Info

Publication number
ATE179611T1
ATE179611T1 AT95909937T AT95909937T ATE179611T1 AT E179611 T1 ATE179611 T1 AT E179611T1 AT 95909937 T AT95909937 T AT 95909937T AT 95909937 T AT95909937 T AT 95909937T AT E179611 T1 ATE179611 T1 AT E179611T1
Authority
AT
Austria
Prior art keywords
ns4a
pct
hcv
protease activity
serine protease
Prior art date
Application number
AT95909937T
Other languages
English (en)
Inventor
Francesco Raffaele De
Cristina Failla
Licia Tomei
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Application granted granted Critical
Publication of ATE179611T1 publication Critical patent/ATE179611T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT95909937T 1994-02-23 1995-02-14 Verfahrenm zum in vitro herstellung der proteolytischen wirkung von ns3 hepatitis c virus (hcv) ATE179611T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM940092A IT1272179B (it) 1994-02-23 1994-02-23 Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.

Publications (1)

Publication Number Publication Date
ATE179611T1 true ATE179611T1 (de) 1999-05-15

Family

ID=11402272

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909937T ATE179611T1 (de) 1994-02-23 1995-02-14 Verfahrenm zum in vitro herstellung der proteolytischen wirkung von ns3 hepatitis c virus (hcv)

Country Status (14)

Country Link
US (1) US5739002A (de)
EP (1) EP0746333B1 (de)
JP (1) JP3280384B2 (de)
AT (1) ATE179611T1 (de)
AU (1) AU691259B2 (de)
BR (1) BR9506931A (de)
CA (1) CA2182521C (de)
DE (1) DE69509504T2 (de)
DK (1) DK0746333T3 (de)
ES (1) ES2132644T3 (de)
GR (1) GR3030166T3 (de)
IT (1) IT1272179B (de)
RU (1) RU2149185C1 (de)
WO (1) WO1995022985A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
US5767233A (en) * 1995-05-12 1998-06-16 Schering Corporation Soluble cleavable substrates of the hepatitis C virus protease
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
AU2933797A (en) * 1996-05-10 1997-12-05 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
US5990276A (en) * 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
US6153579A (en) * 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
EP1364961B1 (de) * 1996-09-12 2006-11-22 Vertex Pharmaceuticals Incorporated Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle
US5861297A (en) * 1996-09-27 1999-01-19 Merck & Co., Inc. Detergent-free hepatitis C protease
AU4904397A (en) * 1996-10-17 1998-05-11 Chiron Corporation Protease regulator screening assay
WO1998037180A2 (en) * 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
US6251583B1 (en) 1998-04-27 2001-06-26 Schering Corporation Peptide substrates for HCV NS3 protease assays
US6280940B1 (en) 1998-08-05 2001-08-28 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
IL143798A0 (en) * 1999-01-08 2002-04-21 Bristol Myers Squibb Co Hepatitis c virus ns3 protease
WO2001002424A2 (en) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
JP2003514562A (ja) * 1999-11-23 2003-04-22 バイロファーマ・インコーポレイテッド ポリメラーゼ組成物およびその使用方法
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SK742003A3 (en) * 2000-07-21 2003-06-03 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
US7012066B2 (en) * 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP2050822B1 (de) 2001-01-23 2013-07-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis C-Virus-Replicone und repliconerweiterte Zellen
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
JP4475561B2 (ja) 2001-10-11 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション C型肝炎ウイルスワクチン
ES2344253T3 (es) 2001-10-11 2010-08-23 MERCK SHARP & DOHME CORP. Vacuna contra el virus de la hepatitis c.
ATE426682T1 (de) * 2002-04-16 2009-04-15 Merck & Co Inc Hepatitis-c-virus-testsysteme
DE602004024658D1 (de) * 2003-02-13 2010-01-28 Merck & Co Inc Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate
US7414031B2 (en) * 2004-11-22 2008-08-19 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
HRP20070435A9 (en) * 2005-02-28 2008-09-30 Genelabs Technologies Tricyclic-nucleoside compounds for treating viral infections
US7834145B2 (en) * 2005-03-22 2010-11-16 Merck Sharp & Dohme Corp. HCV protease substrates
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
JP2008546802A (ja) * 2005-06-24 2008-12-25 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルスを治療するためのヘテロアリール誘導体
EP1945797B1 (de) * 2005-10-28 2012-05-30 Boehringer Ingelheim International GmbH Hepatitis-c-virus-ns2/3-aktivitätstest
EP2029741A4 (de) 2006-06-08 2011-03-16 Merck Sharp & Dohme Schnellverfahren zur bestimmung der hemmersensitivität von aus klinischen proben geklonten ns3/4a-proteasesequenzen
PE20081113A1 (es) * 2006-07-20 2008-10-03 Genelabs Tech Inc Inhibidores virales policiclicos
US20100216161A1 (en) 2009-02-26 2010-08-26 Vertex Pharmaceuticals Incorporated Method for identifying protease inhibitors
US20100143886A1 (en) 2007-03-09 2010-06-10 Ludmerer Steven W In vivo hcv resistance to anti-viral inhibitors
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
EA201300160A1 (ru) 2010-07-22 2013-06-28 Новартис Аг 2,3,5-тризамещенные тиофены и их применение
WO2012092484A2 (en) 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
WO2019147478A2 (en) 2018-01-18 2019-08-01 California Institute Of Technology Programmable protein circuits in living cells
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
US11542305B2 (en) 2018-08-31 2023-01-03 California Institute Of Technology Synthetic protein circuits detecting signal transducer activity
WO2020146627A1 (en) 2019-01-10 2020-07-16 California Institute Of Technology A synthetic system for tunable thresholding of protein signals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7675491A (en) * 1990-04-04 1991-10-30 Chiron Corporation Hepatitis c virus protease

Also Published As

Publication number Publication date
DK0746333T3 (da) 1999-11-01
IT1272179B (it) 1997-06-16
DE69509504D1 (de) 1999-06-10
DE69509504T2 (de) 1999-09-02
ES2132644T3 (es) 1999-08-16
US5739002A (en) 1998-04-14
EP0746333A1 (de) 1996-12-11
CA2182521C (en) 1999-07-06
RU2149185C1 (ru) 2000-05-20
AU691259B2 (en) 1998-05-14
HK1010988A1 (en) 1999-07-02
AU1822395A (en) 1995-09-11
JPH10500005A (ja) 1998-01-06
ITRM940092A0 (it) 1994-02-23
BR9506931A (pt) 1997-09-09
WO1995022985A1 (en) 1995-08-31
GR3030166T3 (en) 1999-08-31
JP3280384B2 (ja) 2002-05-13
CA2182521A1 (en) 1995-08-31
ITRM940092A1 (it) 1995-08-23
EP0746333B1 (de) 1999-05-06

Similar Documents

Publication Publication Date Title
DE69509504D1 (de) Verfahrenm zum in vitro herstellung der proteolytischen wirkung von ns3 hepatitis c virus (hcv)
RU96119350A (ru) Способ репродукции in vitro протеолитической активности ns3 протеазы вируса гепатита c(нсу)
AU638133B2 (en) Ribosome inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
ATE291616T1 (de) Neue carbonyl-reduktase, gen davon und verfahren der anwendung derselben
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
DE69332714D1 (de) Dna verbindungen mit mannuronan c-5-epimerase kodierenden sequenzen
DE68929484D1 (de) Proteolytische Enzyme und ihre Verwendung in Waschmitteln
IL152022A0 (en) Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
NZ283995A (en) Customized (mutant) carboxypeptidase Y having modified S1 subsite
ATE216400T1 (de) Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle
ATE317912T1 (de) Verfahren zur herstellung von beta-lactamen
PT846164E (pt) Metodologia para produzir, purificar e analisar polipeptidos com a actividade proteolitica da protease hcv ns3
NZ506346A (en) Enzymes modified by site directed mutagenesis where amino acids have been replaced by cysteine residues that have a modified thiol group
MX9708679A (es) Sustratos disociables, solubles de la proteasa del virus de la hepatitis c.
ATE211169T1 (de) Dipeptidylaminopeptidase von dictyostelium
MXPA05003713A (es) Metodo de purificacion de lantibioticos.
ATE310013T1 (de) Herstellung von n-(n-(3,3-dimethylbutyl)-l-alpha- aspartyl)-l-phenylalanin-1-methylester durch verwendung vom l-alpha-aspartyl-l-phenylalanin-1- methylester als vorläufer
JPS6437298A (en) Production of c-terminal amidated peptide
GB0006537D0 (en) Assays and screening methods
ATE236990T1 (de) Verfahren zur herstellung von optisch aktiven alpha-aminonitrilen
EP0381331A3 (de) Gensequenzen, die modifizierte Reste in der Proteasedomäne des t-PAs codieren
ATE238344T1 (de) Synthese und gewinnung von aspartam, unter anwendung eines enzymatischen deformylationsschrittes
DE3882654D1 (de) Enzymhemmer und methode zu dessen herstellung.
NO944411L (no) Endoprotease med en ny spaltningsspesifisitet

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification